This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ICN Gets Cautious on Outlook

ICN Pharmaceuticals (ICN) said Tuesday that it is "no longer comfortable" with its year-end earnings guidance, adding that it isn't ready to adjust its earnings predictions at this time.

As a result, shares of the Costa Mesa, Calif.-based company ended down 4.1%, or 66 cents, at $15.48. The company also reported second-quarter earnings that fell below analysts' estimates.

ICN said its previous year-end earnings guidance of $1.20 to $1.25 per share was contingent, in part, on a steady stream of royalty revenue from ribavirin, a treatment for hepatitis C licensed to Schering-Plough (SGP), which sells the drug under the brand name Rebetol in major world markets.

Schering-Plough also sells Rebetron, a drug that combines Rebetol and Schering-Plough's Intron interferon. ICN also licenses ribavirin to Hoffmann La Roche, which sells the drug under the brand name Copegus.

But ICN's second-quarter earnings report issued Tuesday showed that royalty revenue dropped to $51.96 million for the three months ended June 30, compared with $66 million for the same period last year.

Robert W. O'Leary, ICN's chairman and chief executive, said Tuesday that the royalty problem may be exacerbated because of a federal court judge's ruling in California last month that said three generic drug companies aren't infringing on ribavirin patents. However, the court didn't rule on the validity of the patents for the hepatitis C drug.

ICN and Ribapharm (RNA), a spinoff of ICN that makes ribavirin, had sued the generic drugmakers. Both companies said they plan to appeal the judge's decision. ICN still owns 80% of Ribapharm and is trying to buy back the remaining 20%.

The court's ruling prompted Standard & Poor's on July 17 to cut its corporate credit rating for ICN to BB-minus from BB and to lower its rating to B from B-plus its rating on ICN's 6.5% convertible notes due July 15, 2008. S&P, whose outlook on ICN is "negative," said the speculative-grade ratings on ICN reflect the fact that ribavirin royalties have accounted for 37% of the company's revenue, as well as the uncertainty about its restructuring efforts.

S&P said ICN's royalty revenue stream is expected to weaken if the generic competitors prevail and if Hoffmann La Roche continues to make market share inroads against Schering-Plough in the hepatitis C market for drugs combining ribavirin and interferon.
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ICN $21.14 0.62%
RNA $18.65 0.00%
AAPL $111.31 0.48%
FB $92.80 -1.29%
GOOG $645.44 0.62%


Chart of I:DJI
DOW 16,790.19 +13.76 0.08%
S&P 500 1,979.92 -7.13 -0.36%
NASDAQ 4,748.3610 -32.9030 -0.69%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs